

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Trumenba suspension for injection in pre-filled syringe

Meningococcal group B vaccine (recombinant, adsorbed)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 dose (0.5 ml) contains:

<i>Neisseria meningitidis</i> serogroup B fHbp subfamily A ^{1,2,3}	60 micrograms
---	---------------

<i>Neisseria meningitidis</i> serogroup B fHbp subfamily B ^{1,2,3}	60 micrograms
---	---------------

¹ Recombinant lipidated fHbp (factor H binding protein)

² Produced in *Escherichia coli* cells by recombinant DNA technology

³ Adsorbed on aluminium phosphate (0.25 milligram aluminium per dose)

Excipients with known effect

Trumenba contains 0.018 mg of polysorbate 80 in each 0.5 mL dose, which is equivalent to 0.035 mg/mL of polysorbate 80.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Suspension for injection.

White liquid suspension.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroup B.

See section 5.1 for information on the immune response against specific serogroup B strains.

The use of this vaccine should be in accordance with official recommendations.

4.2 Posology and method of administration

Posology

Primary series

2 doses: (0.5 ml each) administered at a 6 month interval (see section 5.1).

3 doses: 2 doses (0.5 ml each) administered at least 1 month apart, followed by a third dose at least 4 months after the second dose (see section 5.1).

Booster dose

A booster dose should be considered following either dosing regimen for individuals at continued risk of invasive meningococcal disease (see section 5.1).

Other paediatric populations

Safety and efficacy of Trumenba in children younger than 10 years of age have not been established. Currently available data in infants are described in section 4.8 and for children 1 to 9 years of age are described in sections 4.8 and 5.1; however, no recommendation on a posology can be made as data are limited.

Trumenba should not be used in infants aged 2 to 6 months because of safety concerns (see section 4.8).

Method of administration

For intramuscular injection only. The preferred site for injection is the deltoid muscle of the upper arm.

For instructions on the handling of the vaccine before administration, see section 6.6.

There are no data available on the interchangeability of Trumenba with other meningococcal group B vaccines to complete the vaccination series.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered product should be clearly recorded.

Hypersensitivity

Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Syncope

As with other injectable vaccines, syncope (fainting) can occur in association with administration of Trumenba. Procedures should be in place to avoid injury from fainting.

Concurrent acute illness

Vaccination should be postponed in individuals suffering from an acute severe febrile illness. However, the presence of a minor infection, such as cold, should not result in the deferral of vaccination.

Intramuscular injections

Trumenba should not be administered intravenously, intradermally, or subcutaneously.

Trumenba should not be given to individuals with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection, unless the potential benefit clearly outweighs the risk of administration.

Altered immunocompetence

Immunocompromised individuals, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Trumenba. Immunogenicity data are available in individuals with complement deficiencies or splenic dysfunctions (see section 5.1).

Persons with familial complement deficiencies (for example, C5 or C3 deficiencies) and persons receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* serogroup B, even if they develop antibodies following vaccination with Trumenba.

Protection against meningococcal disease

As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients.

Limitations of clinical trials

There are limited data on the use of Trumenba in individuals 40 to 65 years of age and there are no data on the use of Trumenba in individuals older than 65 years of age.

Excipients

This vaccine contains polysorbate 80 (see section 2). Polysorbate 80 may cause hypersensitivity reactions.

This vaccine contains less than 1 mmol sodium (23 mg) per dose. Individuals on low sodium diets can be informed that this vaccine is essentially sodium-free.

4.5 Interaction with other medicinal products and other forms of interaction

Trumenba can be given concomitantly with any of the following vaccines: Tetanus Toxoid, Reduced Diphtheria Toxoid, Acellular Pertussis, and Inactivated Poliovirus Vaccine (Tdap-IPV), Quadrivalent Human Papillomavirus vaccine (HPV4), Meningococcal Serogroups A, C, W, Y conjugate vaccine (MenACWY) and Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap).

When given concomitantly with other vaccines Trumenba must be administered at a separate injection site.

Trumenba should not be mixed with other vaccines in the same syringe.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of Trumenba in pregnant women. The potential risk for pregnant women is unknown. Nevertheless, vaccination should not be withheld when there is a clear risk of exposure to meningococcal infection.

Reproduction studies performed in female rabbits have revealed no evidence of impaired female fertility or harm to the foetus due to Trumenba.

Breast-feeding

It is unknown whether Trumenba is excreted in human milk. Trumenba should only be used during breast-feeding when the possible advantages outweigh the potential risks.

Fertility

Animal studies do not indicate direct or indirect harmful effects with respect to fertility in females (see section 5.3).

Trumenba has not been evaluated for impairment of fertility in males.

4.7 Effects on ability to drive and use machines

Trumenba has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines.

4.8 Undesirable effects

Summary of the safety profile

The safety profile presented is based on analysis of approximately 17,000 subjects (1 year of age and older) who have been vaccinated with at least 1 dose of Trumenba in completed clinical studies.

In over 16,000 subjects ≥ 10 years of age studied, the most common adverse reactions were headache, diarrhoea, nausea, muscle pain, joint pain, fatigue, chills, and injection site pain, swelling and redness.

Adverse reactions following booster vaccination in 301 subjects 15 to 23 years of age were similar to adverse reactions during the primary Trumenba vaccination series approximately 4 years earlier.

List of adverse reactions

Adverse reactions reported in clinical studies of subjects 10 years of age and older are listed in decreasing order of frequency and seriousness.

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1,000$ to $< 1/100$)

Rare ($\geq 1/10,000$ to $< 1/1,000$)

Very rare ($< 1/10,000$)

Not known (cannot be estimated from available data)

Immune system disorders

Not known: Allergic reactions*

Nervous system disorders

Very Common: Headache

Gastrointestinal disorders

Very Common: Diarrhoea; nausea

Common: Vomiting

Musculoskeletal and connective tissue disorders

Very Common: Muscle pain (myalgia); joint pain (arthralgia)

General disorders and administration site conditions

Very Common: Chills; fatigue; redness (erythema), swelling (induration) and pain at injection site

Common: Fever $\geq 38^{\circ}\text{C}$ (pyrexia)

*Reported in the postmarketing experience. Because this reaction was derived from spontaneous reports, the frequency could not be determined and is thus considered as not known.

Paediatric population < 10 years of age

Children/toddlers

In a study of 294 children 2 to 9 years of age, the following adverse reactions occurred at a frequency of very common ($\geq 1/10$): headache, diarrhoea, vomiting, muscle pain, joint pain, fever, fatigue, and injection site pain, swelling and redness. Fever ($\geq 38^{\circ}\text{C}$) was reported in 24.5% of subjects.

In a study of 220 toddlers 1 to < 2 years of age, the following adverse reactions occurred at a frequency of very common ($\geq 1/10$): drowsiness, irritability (fussiness), loss of or decreased appetite, fever, and injection site pain, swelling and redness. Fever ($\geq 38^{\circ}\text{C}$) was reported in 37.3% of subjects.

In clinical studies, fever ($\geq 38^{\circ}\text{C}$) occurred more frequently as subject age decreased. Fever followed a predictable pattern after vaccination: onset occurred within 2 to 4 days, lasted 1 day, and was mild to moderate in severity. Fever rate and severity tended to decrease with subsequent Trumenba vaccinations.

Booster vaccination in children

Adverse reactions following a booster vaccination in 147 subjects 3 to 5 years of age were similar to adverse reactions during the primary Trumenba vaccination series approximately 2 years earlier.

Infants less than 1 year of age

In a study including 115 infants 2 months and 48 infants 6 months of age who received Trumenba or an investigational combination meningococcal vaccine containing Trumenba co-administered with vaccines licensed for this age group, the following adverse reactions occurred at a frequency of very common ($\geq 1/10$): drowsiness, irritability (fussiness), loss of or decreased appetite, fever, and injection site pain, swelling and redness.

Fever ($\geq 38^{\circ}\text{C}$) was reported in 74% of subjects, with 69% of subjects (33 out of 48) 6 months of age reporting fever and 76% of subjects (87 out of 115) 2 months of age. Occurrence of fever $> 38.9^{\circ}\text{C}$ - 40.0°C was very common (12.0-25.0%) in both age groups, despite the use of paracetamol. The rate and severity of fever did not decrease with the second vaccination in the youngest infants.

The study was terminated as two infants 2 months of age developed fever (39.3 °C and 39 °C, respectively) after the first vaccination that, despite the use of antipyretics, led to medical attention and investigations including lumbar puncture. Cerebrospinal fluid (CSF) analysis showed pleocytosis without positive microbiological test results in 1 infant. Both cases were treated as presumed infections. Symptoms resolved for both infants. Postmarketing data revealed 3 additional cases in which infants 1 to 3 months of age experienced fever leading to medical attention and investigations including lumbar puncture 1 day after administration of Trumenba. CSF analysis showed no pleocytosis in 2 cases and in 1 case showed pleocytosis without a positive microbiological test result.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance. Website: www.hpra.ie.

4.9 Overdose

Experience of overdose is limited. In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: vaccines; ATC code: J07AH09

Mechanism of action

Trumenba is a vaccine composed of 2 recombinant lipidated factor H binding protein (fHbp) variants. fHbp is found on the surface of meningococcal bacteria and helps bacteria to avoid host immune defenses. fHbp variants segregate into 2 immunologically distinct subfamilies, A and B, and over 96% of meningococcal serogroup B isolates in Europe express fHbp variants from either subfamily on the bacterial surface.

Immunisation with Trumenba, which contains one fHbp variant each from subfamily A and B, is intended to stimulate the production of bactericidal antibodies that recognise fHbp expressed by meningococci. The Meningococcal Antigen Surface Expression (MEASURE) assay was developed to relate the level of fHbp surface expression to killing of meningococcal serogroup B strains in serum bactericidal assays with human complement (hSBAs). A survey of over 2,150 different invasive meningococcal serogroup B isolates collected from 2000-2014 in 7 European countries, the US and Canada demonstrated that over 91% of all meningococcal serogroup B isolates expressed sufficient levels of fHbp to be susceptible to bactericidal killing by vaccine-induced antibodies.

Clinical efficacy

The efficacy of Trumenba has not been evaluated through clinical trials. Vaccine efficacy has been inferred by demonstrating the induction of serum bactericidal antibody responses to 4 meningococcal serogroup B test strains (see the Immunogenicity section). The 4 test strains express fHbp variants representing the 2 subfamilies (A and B) and, when taken together, are representative of meningococcal serogroup B strains causing invasive disease.

Immunogenicity

Protection against invasive meningococcal disease is mediated by serum bactericidal antibodies to bacterial surface antigens. Bactericidal antibodies act in concert with human complement to kill meningococci. This process is measured *in vitro* with hSBA for meningococcal serogroup B. An hSBA titre of $\geq 1:4$ is assumed to be protective against meningococcal disease. In the immunogenicity analysis for Trumenba, a more conservative hSBA titre threshold of $\geq 1:8$ or $1:16$ was applied, depending on the hSBA strain.

Vaccine coverage was investigated using four primary representative meningococcal serogroup B test strains: two expressing subfamily A fHbp (variants A22 and A56) and two expressing subfamily B fHbp (variants B24 and B44). To support and further extend the breadth of vaccine coverage, an additional 10 meningococcal serogroup B test strains were used; these included six expressing subfamily A fHbp (variants A06, A07, A12, A15, A19 and A29) and four expressing subfamily B fHbp (variants B03, B09, B15 and B16).

Immunogenicity in subjects 10 years of age and older

The immunogenicity of Trumenba described in this section includes results from Phase 2 and Phase 3 clinical studies:

- Following the 2-dose schedule (0 and 6 months) in subjects 10 to 25 years of age in the US and Europe (Study B1971057);
- Following the 3-dose schedule (0, 2, and 6 months) in subjects 10 to 25 years of age globally (Studies B1971009 and B1971016); and
- Following the 2-dose (0 and 6 months) and 3-dose schedules (0, 1-2, and 6 months) in subjects 11 to 18 years of age in Europe (Study B1971012).

Study B1971057 is a Phase 3, randomised, active-controlled, observer-blinded, multicentre trial in which subjects 10 to 25 years of age received Trumenba at months 0 and 6 (coadministered with MenACWY-CRM for the first dose) or an investigational pentavalent meningococcal vaccine at months 0 and 6. A total of 1,057 subjects received Trumenba and 543 subjects received the investigational control. The hSBA titres for primary test strains are presented in Table 1. Table 2 presents the hSBA titres against the additional 10 test strains which support and extend the breadth of vaccine coverage demonstrated by the 4 representative primary strains.

Table 1: hSBA titres among subjects 10 to 25 years of age receiving Trumenba on a 0- and 6-month schedule for primary strains 1 month post-dose 2 (Study B1971057)									
	≥ 4-fold rise ⁽¹⁾		Titre ≥ 1:8 ⁽²⁾		GMT ⁽³⁾	Composite ⁽⁴⁾			
						Pre-vaccination 1		Post-dose 2	
Strain	N	% (95% CI)	N	% (95% CI)	GMT (95% CI)	N	% (95% CI)	N	% (95% CI)
A22	827	73.8 (70.6, 76.7)	852	91.0 (88.8, 92.8)	49.3 (46.2, 52.6)	799	1.8 (1.0, 2.9)	814	74.3 (71.2, 77.3)
A56	823	95.0 (93.3, 96.4)	854	99.4 (98.6, 99.8)	139.5 (130.6, 149.1)				
B24	835	67.4 (64.1, 70.6)	842	79.3 (76.4, 82.0)	21.2 (19.6, 22.9)				
B44	850	86.4 (83.9, 88.6)	853	94.5 (92.7, 95.9)	37.8 (35.1, 40.8)				
Abbreviations: GMT=geometric mean titre; hSBA=serum bactericidal assay using human complement.									
⁽¹⁾ A ≥ 4-fold rise is defined as (i) A hSBA titre ≥ 1:16 for subjects with a baseline hSBA titre < 1:4. (ii) Four times the 1:8 or 16 threshold or four times the baseline hSBA titre, whichever is higher for subjects with a baseline hSBA titre ≥ 1:4.									
⁽²⁾ All strains used a 1:8 titre threshold except A22 which was 1:16.									
⁽³⁾ N for GMT is the same as that presented in preceding titre ≥ 1:8 or 16 column.									
⁽⁴⁾ Proportion of subjects with a composite of hSBA titres ≥ 1:8 or 16 for all four primary strains combined									

Table 2: hSBA titres among subjects 10 to 25 years of age receiving Trumenba on a 0- and 6-month schedule for additional strains 1 month post-dose 2 (Study B1971057)

	N	% titre $\geq 1:8^{(1)}$	95% CI
A06	159	89.3	83.4, 93.6
A07	157	96.8	92.7, 99.0
A12	157	83.4	76.7, 88.9
A15	165	89.1	83.3, 93.4
A19	167	90.4	84.9, 94.4
A29	166	95.2	90.7, 97.9
B03	164	74.4	67.0, 80.9
B09	166	71.1	63.6, 77.8
B15	167	85.0	78.7, 90.1
B16	164	77.4	70.3, 83.6

Abbreviations: hSBA=serum bactericidal assay using human complement.
⁽¹⁾ All strains used a 1:8 titre threshold except A06, A12 and A19 which were 1:16.

Study B1971009 was a Phase 3, randomised, active-controlled, observer-blinded, multicentre trial in which subjects 10 to 18 years of age received 1 of 3 lots of Trumenba or the active control hepatitis A virus (HAV) vaccine/saline (control). A total of 2,693 subjects received at least 1 dose of Trumenba and 897 received at least 1 dose of HAV vaccine/saline. The study assessed the safety, tolerability, immunogenicity, and demonstration of manufacturability of 3 lots of Trumenba administered on a 0-, 2-, and 6-month schedule. The hSBA titres for primary test strains observed after the third dose in lot 1 and the control are presented in Table 3. Results from lots 2 and 3 are not presented, as only 2 representative strains were evaluated. Similar results were observed for lots 2 and 3 as observed for lot 1.

Study B1971016 was a Phase 3, randomised, placebo-controlled, observer-blinded, multicentre trial in which subjects 18 to 25 years of age were assigned to receive either Trumenba at months 0, 2, and 6 or saline at months 0, 2, and 6 in a 3:1 ratio. A total of 2,471 subjects received Trumenba and 822 received saline. The hSBA titres for primary test strains observed after the third dose are presented in Table 3.

Table 3. hSBA titres among subjects 10 to 25 years of age 1 month post-dose 3 of Trumenba or control on a 0-, 2-, and 6-month schedule for primary strains (Study B1971009 and Study B1971016)

		Study B1971009 (10-18 years of age)				Study B1971016 (18-25 years of age)			
		Trumenba		HAV/saline		Trumenba		Saline	
Strain		N	% or GMT (95% CI)	N	% or GMT (95% CI)	N	% or GMT (95% CI)	N	% or GMT (95% CI)
A22	≥ 4 -fold rise ⁽¹⁾	1225	83.2 (81.0, 85.2)	730	9.6 (7.6, 12.0)	1695	80.5 (78.6, 82.4)	568	6.3 (4.5, 8.7)
	hSBA $\geq 1:16$	1266	97.8 (96.8, 98.5)	749	34.0 (30.7, 37.6)	1714	93.5 (92.2, 94.6)	577	36.6 (32.6, 40.6)
	hSBA GMT	1266	86.8 (82.3, 91.5)	749	12.6 (12.0, 13.4)	1714	74.3 (70.2, 78.6)	577	13.2 (12.4, 14.1)
A56	≥ 4 -fold rise ⁽¹⁾	1128	90.2 (88.4, 91.9)	337	11.3 (8.1, 15.1)	1642	90.0 (88.4, 91.4)	533	10.3 (7.9, 13.2)

Table 3. hSBA titres among subjects 10 to 25 years of age 1 month post-dose 3 of Trumenba or control on a 0-, 2-, and 6-month schedule for primary strains (Study B1971009 and Study B1971016)									
		Study B1971009 (10-18 years of age)				Study B1971016 (18-25 years of age)			
		Trumenba		HAV/saline		Trumenba		Saline	
Strain		N	% or GMT (95% CI)	N	% or GMT (95% CI)	N	% or GMT (95% CI)	N	% or GMT (95% CI)
	hSBA $\geq$ 1:8	1229	99.5 (98.9, 99.8)	363	27.5 (23.0, 32.5)	1708	99.4 (98.9, 99.7)	552	34.2 (30.3, 38.4)
	hSBA GMT	1229	222.5 (210.1, 235.6)	363	8.8 (7.6, 10.1)	1708	176.7 (167.8, 186.1)	552	9.1 (8.2, 10.1)
B24	$\geq$ 4-fold rise⁽¹⁾	1235	79.8 (77.4, 82.0)	752	2.7 (1.6, 4.1)	1675	79.3 (77.3, 81.2)	562	5.5 (3.8, 7.7)
	hSBA $\geq$ 1:8	1250	87.1 (85.1, 88.9)	762	7.0 (5.3, 9.0)	1702	95.1 (93.9, 96.0)	573	30.2 (26.5, 34.1)
	hSBA GMT	1250	24.1 (22.7, 25.5)	762	4.5 (4.4, 4.7)	1702	49.5 (46.8, 52.4)	573	7.2 (6.6, 7.8)
B44	$\geq$ 4-fold rise⁽¹⁾	1203	85.9 (83.8, 87.8)	391	1.0 (0.3, 2.6)	1696	79.6 (77.6, 81.5)	573	1.6 (0.7, 3.0)
	hSBA $\geq$ 1:8	1210	89.3 (87.4, 90.9)	393	5.3 (3.3, 8.1)	1703	87.4 (85.8, 89.0)	577	11.4 (9.0, 14.3)
	hSBA GMT	1210	50.9 (47.0, 55.2)	393	4.4 (4.2, 4.6)	1703	47.6 (44.2, 51.3)	577	4.8 (4.6, 5.1)
Composite⁽²⁾									
Pre-vaccination 1		1088	1.1 (0.6, 1.9)	354	2.0 (0.8, 4.0)	1612	7.3 (6.0, 8.6)	541	6.1 (4.2, 8.5)
Post-dose 3		1170	83.5 (81.3, 85.6)	353	2.8 (1.4, 5.1)	1664	84.9 (83.1, 86.6)	535	7.5 (5.4, 10.0)
Abbreviations: GMT=geometric mean titre; hSBA=serum bactericidal assay using human complement; HAV=hepatitis A virus vaccine.									
⁽¹⁾ A $\geq$ 4-fold rise is defined as (i) A hSBA titre $\geq$ 1:16 for subjects with a baseline hSBA titre $<$ 1:4. (ii) Four times the 1:8/16 threshold or four times the baseline hSBA titre, whichever is higher for subjects with a baseline hSBA titre $\geq$ 1:4.									
⁽²⁾ Proportion of subjects with a composite of hSBA titres $\geq$ 1:8 or 16 for all four primary strains combined.									

In Studies B1971009 and B1971016, the proportion of subjects achieving a hSBA titre $\geq$ 1:8 (variants A07, A15, A29, B03, B09, B15, B16) or 1:16 (variants A06, A12, A19) against the 10 additional test strains after 3 doses of Trumenba, administered on a 0-, 2-, and 6-month schedule, was determined. Across the two studies, the majority of subjects, ranging from 71.3% to 99.3% for the 6 subfamily A fHbp strains and 77.0% to 98.2% for the 4 subfamily B fHbp strains, achieved a hSBA titre $\geq$ 1:8 or 16, consistent with the results observed with the 4 primary test strains.

In Study B1971012, a Phase 2 study in subjects 11 to 18 years of age in Europe, hSBA titres following completion of two 3-dose schedules (0, 1, and 6 months and 0, 2, and 6 months) and a 2-dose schedule (0 and 6 months) were determined against the 4 primary test strains. At 1 month after the third dose, similar robust and broad immune responses were observed for both 3-dose schedules with 86.1% to 99.4% achieving hSBA titres $\geq$ 1:8 or 16 and 74.6% to 94.2% achieving a 4-fold increase in hSBA titre. At 1 month after completion of the 2-dose schedule (0 and 6 months), 77.5% to 98.4% achieved hSBA titres $\geq$ 1:8 or 16 and 65.5% to 90.4% achieved a 4-fold increase in hSBA titre.

Study B1971033 was an open-label, follow-up study of subjects previously enrolled in a primary study, including Study B1971012. Subjects attended visits over 4 years for collection of blood samples and received a single booster dose of Trumenba approximately 4 years after receipt of a

primary series of 2 or 3 doses of Trumenba. hSBA titres 4 years after the primary series and 26 months after the booster dose for subjects enrolled from primary Study B1971012 Group 1 (0, 1, and 6 months), Group 2 (0, 2, and 6 months), and Group 3 (0 and 6 months) are presented in Table 4. A booster response was observed as measured by hSBA at 1 month following a dose of Trumenba approximately 4 years after a primary series of 2 doses (Group 3) or 3 doses (Groups 1 and 2).

Table 4: hSBA titres among subjects 11 to 18 years of age receiving Trumenba on a 0-, 1-, 6-month; 0-, 2-, and 6-month; and 0- and 6-month schedules and a booster 4 years after primary series completion (Study B1971033)

Strain	Timepoint		Primary Study B1971012 Vaccine Groups (as Randomised)								
			0, 1, and 6 months			0, 2, and 6 months			0 and 6 months		
			N	% ≥ 1:8 ⁽¹⁾ (95% CI)	GMT (95% CI)	N	% ≥ 1:8 ⁽¹⁾ (95% CI)	GMT (95% CI)	N	% ≥ 1:8 ⁽¹⁾ (95% CI)	GMT (95% CI)
A22	Post-primary	month 1	59	89.8 (79.2, 96.2)	53.0 (40.4, 69.6)	57	91.2 (80.7, 97.1)	59.5 (45.5, 77.8)	61	98.4 (91.2, 100.0)	55.8 (46.2, 67.4)
		month 12	99	41.4 (31.6, 51.8)	14.9 (12.6, 17.7)	111	45.0 (35.6, 54.8)	15.8 (13.4, 18.6)	113	36.3 (27.4, 45.9)	15.6 (13.0, 18.8)
		month 48	59	49.2 (35.9, 62.5)	16.6 (13.0, 21.1)	57	56.1 (42.4, 69.3)	20.7 (15.6, 27.4)	61	55.7 (42.4, 68.5)	16.6 (13.4, 20.5)
	Post-booster	month 1	59	100.0 (93.9, 100.0)	126.5 (102.7, 155.8)	58	100.0 (93.8, 100.0)	176.7 (137.8, 226.7)	60	96.7 (88.5, 99.6)	142.0 (102.9, 196.1)
		month 12	58	74.1 (61.0, 84.7)	33.6 (24.5, 46.1)	54	77.8 (64.4, 88.0)	44.1 (31.2, 62.4)	60	80.0 (67.7, 89.2)	31.6 (23.5, 42.5)
		month 26	0	NE ⁽²⁾	NE ⁽²⁾	34	73.5 (55.6, 87.1)	34.7 (23.0, 52.4)	42	61.9 (45.6, 76.4)	27.1 (18.6, 39.6)
A56	Post-primary	month 1	58	100.0 (93.8, 100.0)	158.7 (121.5, 207.3)	57	98.2 (90.6, 100.0)	191.2 (145.8, 250.8)	62	98.4 (91.3, 100.0)	143.1 (109.6, 187.0)
		month 12	98	73.5 (63.6, 81.9)	25.7 (19.4, 34.0)	109	76.1 (67.0, 83.8)	27.3 (21.0, 35.4)	106	60.4 (50.4, 69.7)	18.5 (13.8, 24.7)
		month 48	53	43.4 (29.8, 57.7)	10.7 (7.4, 15.3)	55	56.4 (42.3, 69.7)	15.0 (10.2, 22.2)	62	43.5 (31.0, 56.7)	10.8 (7.6, 15.3)
	Post-booster	month 1	57	100.0 (93.7, 100.0)	359.8 (278.7, 464.7)	56	100.0 (93.6, 100.0)	414.8 (298.8, 575.9)	62	98.4 (91.3, 100.0)	313.1 (221.3, 442.8)
		month 12	55	90.9 (80.0, 97.0)	47.3 (34.3, 65.3)	55	89.1 (77.8, 95.9)	64.0 (42.6, 96.2)	59	81.4 (69.1, 90.3)	41.0 (26.7, 62.7)
		month 26	0	NE ⁽²⁾	NE ⁽²⁾	29	82.8 (64.2, 94.2)	37.8 (21.3, 67.2)	40	57.5 (40.9, 73.0)	16.0 (9.9, 25.8)
B24	Post-primary	month 1	59	88.1 (77.1, 95.1)	25.6 (19.7, 33.3)	58	91.4 (81.0, 97.1)	30.5 (23.8, 39.1)	60	85.0 (73.4, 92.9)	29.2 (21.5, 39.6)
		month 12	98	40.8 (31.0, 51.2)	9.7 (7.5, 12.4)	108	49.1 (39.3, 58.9)	11.5 (9.0, 14.6)	103	36.9 (27.6, 47.0)	8.4 (6.7, 10.6)
		month 48	59	40.7 (28.1, 54.3)	10.7 (7.6, 15.1)	57	49.1 (35.6, 62.7)	11.4 (8.2, 15.9)	62	40.3 (28.1, 53.6)	8.9 (6.8, 11.8)
	Post-booster	month 1	58	100.0 (93.8, 100.0)	94.9 (74.6, 120.9)	57	100.0 (93.7, 100.0)	101.6 (83.1, 124.2)	62	96.8 (88.8, 99.6)	79.1 (60.6, 103.5)
		month 12	58	65.5 (51.9, 77.5)	21.1 (14.2, 31.3)	54	74.1 (60.3, 85.0)	25.7 (17.7, 37.5)	62	77.4 (65.0, 87.1)	22.4 (16.4, 30.5)
		month 26	0	NE ⁽²⁾	NE ⁽²⁾	33	78.8 (61.1, 91.0)	24.4 (16.1, 36.8)	42	59.5 (43.3, 74.4)	14.5 (9.9, 21.3)

Table 4: hSBA titres among subjects 11 to 18 years of age receiving Trumenba on a 0-, 1-, 6-month; 0-, 2-, and 6-month; and 0- and 6-month schedules and a booster 4 years after primary series completion (Study B1971033)

Completion (Study B1971012)											
Strain	Timepoint		Primary Study B1971012 Vaccine Groups (as Randomised)								
			0, 1, and 6 months			0, 2, and 6 months			0 and 6 months		
			N	% ≥ 1:8 ⁽¹⁾ (95% CI)	GMT (95% CI)	N	% ≥ 1:8 ⁽¹⁾ (95% CI)	GMT (95% CI)	N	% ≥ 1:8 ⁽¹⁾ (95% CI)	GMT (95% CI)
B44	Post-primary	month 1	58	86.2 (74.6, 93.9)	46.3 (31.7, 67.8)	57	89.5 (78.5, 96.0)	50.2 (35.3, 71.3)	60	81.7 (69.6, 90.5)	35.5 (24.5, 51.4)
		month 12	100	24.0 (16.0, 33.6)	6.4 (5.2, 7.8)	111	22.5 (15.1, 31.4)	6.0 (5.1, 7.2)	115	16.5 (10.3, 24.6)	5.6 (4.8, 6.5)
		month 48	57	36.8 (24.4, 50.7)	8.3 (6.3, 11.0)	57	35.1 (22.9, 48.9)	7.6 (5.8, 10.0)	62	12.9 (5.7, 23.9)	4.6 (4.1, 5.1)
	Post-booster	month 1	59	100.0 (93.9, 100.0)	137.3 (100.3, 188.0)	58	100.0 (93.8, 100.0)	135.9 (108.0, 171.0)	61	93.4 (84.1, 98.2)	74.2 (51.6, 106.8)
		month 12	56	75.0 (61.6, 85.6)	23.2 (16.2, 33.2)	53	81.1 (68.0, 90.6)	24.3 (17.8, 33.3)	61	59.0 (45.7, 71.4)	13.3 (9.7, 18.3)
		month 26	0	NE ⁽²⁾	NE ⁽²⁾	33	66.7 (48.2, 82.0)	16.0 (10.4, 24.7)	43	62.8 (46.7, 77.0)	13.6 (9.8, 18.9)
		Composite ⁽³⁾									
	Post-primary	month 1	57	80.7 (68.1, 90.0)	NE	55	87.3 (75.5, 94.7)	NE	57	77.2 (64.2, 87.3)	NE
		month 12	55	10.9 (4.1, 22.2)	NE	51	13.7 (5.7, 26.3)	NE	49	20.4 (10.2, 34.3)	NE
		month 48	51	19.6 (9.8, 33.1)	NE	53	30.2 (18.3, 44.3)	NE	61	9.8 (3.7, 20.2)	NE
	Post-booster	month 1	56	100 (93.6, 100.0)	NE	55	100.0 (93.5, 100.0)	NE	59	91.5 (81.3, 97.2)	NE
		month 12	53	52.8 (38.6, 66.7)	NE	48	64.6 (49.5, 77.8)	NE	57	61.4 (47.6, 74.0)	NE
		month 26	0	NE ⁽²⁾	NE	27	48.1 (28.7, 68.1)	NE	36	44.4 (27.9, 61.9)	NE
		Abbreviations: hSBA=serum bactericidal assay using human complement; NE=not evaluated; GMT=geometric mean titre.									
⁽¹⁾ All strains used a 1:8 titre threshold except A22 which was 1:16.											
⁽²⁾ Subjects were not followed beyond 12 months post booster.											
⁽³⁾ Proportion of subjects with a composite of hSBA titres ≥ 1:8 or 16 for all four primary strains combined.											
Serum samples were analysed concurrently in the same serology campaign for all time points except the 12 months post-primary dose time point for which results are from the interim analysis.											

Immunogenicity in special populations

Individuals 10 years of age and above with complement deficiencies or splenic dysfunction

Study B1971060 was a Phase 4 study in which 53 participants ≥ 10 years of age with anatomic or functional asplenia (N=51) or complement deficiency (N=2) received Trumenba at months 0 and 6, and safety and immunogenicity were compared to historical data from 53 age- and sex-matched healthy controls that received Trumenba on the same schedule. The proportions of subjects with hSBA titres ≥ 1:8 or 16 against the 4 primary test strains after 2 doses of Trumenba 1 month after the second vaccination are presented in Table 5.

Table 5. hSBA titres among immunocompromised subjects ≥ 10 years of age receiving Trumenba on a 0- and 6-month schedule for primary strains 1 month post-dose 2 (Study B1971060), compared to controls (Study B1971057)								
	Study B1971060 (immunocompromised subjects ≥ 10 years of age)				Study B1971057 (historical age- and sex-matched healthy controls)⁽¹⁾			
	Pre-vaccination 1		1 month post-dose 2		Pre-vaccination 1		1 month post-dose 2	
Strain	N	% ≥ 1:8⁽²⁾ (95% CI)	N	% ≥ 1:8⁽²⁾ (95% CI)	N	% ≥ 1:8⁽²⁾ (95% CI)	N	% ≥ 1:8⁽²⁾ (95% CI)
A22	43	32.6 (19.1, 48.5)	44	75.0 (59.7, 86.8)	42	31.0 (17.6, 47.1)	43	95.3 (84.2, 99.4)
A56	43	25.6 (13.5, 41.2)	44	90.9 (78.3, 97.5)	43	23.3 (11.8, 38.6)	44	100.0 (92.0, 100.0)
B24	42	2.4 (0.1, 12.6)	44	70.5 (54.8, 83.2)	43	23.3 (11.8, 38.6)	44	81.8 (67.3, 91.8)
B44	43	9.3 (2.6, 22.1)	43	79.1 (64.0, 90.0)	44	11.4 (3.8, 24.6)	42	92.9 (80.5, 98.5)
Abbreviations: hSBA=serum bactericidal assay using human complement; N=number of participants with valid and determinate hSBA titres for the given strain.								
⁽¹⁾ Healthy controls included subjects ≥ 10 to 25 years of age.								
⁽²⁾ All strains used a 1:8 titre threshold except A22 which was 1:16.								

Immunogenicity in individuals 1 to 9 years of age

The immunogenicity of Trumenba (0-, 2- and 6-month schedule) in toddlers and children 1 to 9 years of age was evaluated in 2 Phase 2 studies. At 1 month following series completion, 81.4% to 100% of subjects achieved a defined hSBA titre threshold against the 4 primary meningococcal test strains (defined as hSBA ≥ 1:16 for A22; ≥ 1:8 for A56, B24 and B44) compared to 0.4% to 6.5% at baseline.

Persistence data following primary series completion in toddlers 1 to < 2 years of age indicate that 12.4%, 59.1%, 10.3%, and 40.4% at 6 months and 3.7%, 22.8%, 3.7%, and 12.5% at 24 months after series completion maintained hSBA titres ≥ 1:8 or 1:16 against the primary test strains A22, A56, B24 and B44, respectively. An anamnestic response was observed when these children received a booster dose at approximately 24 months after primary series completion at 3 to 5 years of age, with 92.6% to 100.0% achieving hSBA titres ≥ 1:8 or 1:16 against the 4 primary strains.

In children 2 to 9 years of age, 6 months following series completion, 32.5%, 82.4%, 15.5% and 10.4% of participants maintained hSBA titres ≥ 1:8 or 1:16 against the primary test strains A22, A56, B24 and B44, respectively. There are no persistence data beyond 6 months or booster dose data in this age group.

See section 4.2 for information on use in children 1 to 9 years of age.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Non-clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity and reproduction and developmental toxicity.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium Chloride
Histidine
Polysorbate 80 (E433)
Water for injections
For adsorbent, see section 2.

6.2 Incompatibilities

Do not mix Trumenba with other vaccines or medicinal products in the same syringe.

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

5 years.

6.4 Special precautions for storage

Store in a refrigerator (2 °C-8 °C).
Syringes should be stored in the refrigerator horizontally to minimize the re-dispersion time.
Do not freeze.

6.5 Nature and contents of container

0.5 ml suspension in a pre-filled syringe (Type I glass) with plastic Luer Lok adapter, chlorobutyl rubber plunger stopper, and a synthetic isoprene bromobutyl rubber tip cap with a plastic rigid tip cap cover with or without needle. The tip cap and rubber plunger of the pre-filled syringe are not made with natural rubber latex.

Pack sizes of 1, 5, and 10 pre-filled syringes, with or without needle.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

During storage, a white deposit and clear supernatant may be observed in the pre-filled syringe containing the suspension.

Before use, the pre-filled syringe should be shaken vigorously to ensure that a homogeneous white suspension is obtained.

Do not use the vaccine if it cannot be re-suspended.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1187/001
EU/1/17/1187/002
EU/1/17/1187/003
EU/1/17/1187/004
EU/1/17/1187/005
EU/1/17/1187/006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24th May 2017
Date of latest renewal: 25th April 2022

10. DATE OF REVISION OF THE TEXT

05/2026

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

Ref: TU 16_0